参考文献/References:
[1] Wolf D,Stachon P,Bode C,et al.Inflammatory mechanisms in atherosclerosis[J].Hamostaseologie,2014,34(1):63-71.
[2] Maekawa Y,Nagai T,Anzai A. Pentraxins:CRP and PTX3 and cardiovascular disease[J].Inflamm Allergy Drug Targets,2011,10(4):229-235.
[3] Croce K,Libby P.Intertwining of thrombosis and inflammation in atherosclerosis [J].Curr Opin Hematol,2007,14(1):55-61.
[4] Bottazzi B,Doni A,Garlanda C,et al.An integrated view of humoral innate immunity:pentraxin as a paradigm[J].Annu Rev Immunol,2010,28:157-183.
[5] Breviario F, Aniello EM,Golay J,et al.Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component[J].Biol Chem,1992,267(31):22190-22197.
[6] Bottazzi B,Garlanda C,Cotena A,et al.The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor:interplay with cellular innate immunity[J]. Immunol Rev,2009,227(1):9-18.
[7] Ishihara T,Haraguchi G,Tezuka D,et al.Diagnosis and assessment of Takayasu arteritis by multiple biomarkers[J].Circulation,2013,77(2):477-483.
[8] Kimura S,Inagaki H,Haraguchi G. Relationships of elevated systemic pentraxin-3 levels with high-risk coronary plaque components and impaired myocardial perfusion after percutaneous coronary intervention in patients with ST-elevation acute myocardial infarction[J].Circulation,2014,78(1):159-169.
[9] Peri G,Introna M,Corradi D,et al.PTX3,a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans[J].Circulation,2000,102(6):636-641.
[10] Nishinari M,Aoyama N,Ogawa Z,et al.Phosphoglucomutase activity as a novel biomarker in patients with acute myocardial infarction[J].Circulation,2012,76(9):2197-2203.
[11] Matsui S, Ishii J,Kitagawa F,et al.Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction[J].Atherosclerosis,2010,210(1):220-225.
[12] Inforzato A,Baldock C,Jowitt T,et al.The angiogenic inhibitor long pentraxin PTX3 forms an asymmetric octamer with two binding sites for FGF2[J].Biol Chem,2010,285(23):17681-17692.
[13] Norata GD,Marchesi P,Pirillo A,et al.Long pentraxin 3,a key component of innate immunity, is modulated by high-density lipoproteins in endothelial cells[J].Arterioscler Thromb Vasc Biol,2008,28(5):925-931.
[14] Nebuloni M,Pasqualini F,Zerbi P,et al.PTX3 expression in the heart tissues of patients with myocardial infarction and infectious myocarditis[J].Cardiovasc Pathol,2011,20(1):e27-e35.
[15] Yamasaki K,Kurimura M,Kasai T,et al.Determination of physiological plasma pentraxin 3(PTX3)levels in healthy populations[J].Clin Chem Lab Med,2009,47(4):471-477.
[16] Jenny NS,Roger S,Richard A.Associations of pentraxin 3 with cardiovascular disease: the multi-ethnic study of atherosclerosis[J].Thromb Haemost,2014,12(6):999-1005.
[17] Karakas MF, Buyukkaya E, Kurt M,et al. Serum pentraxin 3 levels are associated with the complexity and severity of coronary artery disease in patients with stable angina pectoris[J].Investig Med,2013,61(2):278-285.
[18] Matsubara J,Sugiyama S,Nozaki T,et al.Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction[J].J Am Coll Cardiol,2011,57(7):861-869
[19] Büyükkaya E,Karakas MF, Kurt M,et al.The serum pentraxin-3 is elevated in patients with cardiac syndrome X[J]. Turk Kardiyol Dern Ars,2013,41(4):290-295.
[20] Jylhava J,Haarala A, Kahonen M,et al.Pentraxin 3(PTX3)is associated with cardiovascular risk factors: the Health 2000 Survey[J]. Clin Exp Immunol,2011,164(2):211-217.
[21] Inoue K,Sugiyama A,Reid PC,et al.Establishment of a high sensitivity plasma assay for human pentraxin 3 as a marker for unstable angina pectoris[J]. Arterioscler Thromb Vasc Biol,2007,27(1):161-167.
[22] Iwata A,Miura S,Tanaka T,et al. Plasma pentraxin-3 levels are associated with coronary plaque vulnerability and are decreased by statin[J].Coron Artery Dis,2012,23(5):315-321.
[23] Kimura S,Inagaki H,Haraguchi G.Relationships of elevated systemic pentraxin-3 levels with high-risk coronary plaque components and impaired myocardial perfusion after percutaneous coronary intervention in patients with ST-elevation acute myocardial infarction[J].Circulation,2014,78(1):159-169.
[24] Savchenko A, Imamura M, Ohashi R, et al. Expression of pentraxin 3(PTX3)in human atherosclerotic lesions[J].Pathology,2008,215(1):48-55.
[25] Salio M,Chimenti S,Angelis N.Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction[J].Circulation,2008,117(8):1055-1064.
[26] Norata GD,Garlanda C,Catapano AL. The long pentraxin PTX3:a modulator of the immunoinflammatory response in atherosclerosis and cardiovascular diseases[J]. Trends Cardiovasc Med,2010,20(2):35-40.
[27] Nauta AJ,Bottazzi B,Mantovani A.Biochemical and functional characterization of the interaction between pentraxin 3 and C1q[J].Eur Immunol,2003,33(2):465-473.
[28] Deban L, Russo RC, Sironi M.Regulation of leukocyte recruitment by the long pentraxin PTX3[J].Nat Immunol,2010,11(4):328-334.
[29] Maugeri N,Rovere-Querini P,Slavich M.Early and transient release of leukocyte pentraxin 3 during acute myocardial infarction[J].J Immunol,2011,187(2):970-979.
[30] Tomandlova M, Jarkovsky J,Tomandl J. Prognostic value of pentraxin-3 level in patients with STEMI and its relationship with heart failure and markers of oxidative stress[J]. Dis Markers,2015,2015:159051.
[31] Akgul O,Baycan OF,Bulut U.Long-term prognostic value of elevated pentraxin 3 in patients undergoing primary angioplasty for ST-elevation myocardial infarction[J]. Coron Artery Dis,2015,26(7):592-597.
[32] Guo R,Li Y,Wen J.Elevated plasma level of pentraxin-3 predicts in-hospital and 30-day clinical outcomes in patients with non-ST-segment elevation myocardial infarction who have undergone percutaneous coronary intervention[J].Cardiology,2014,129(3):178-188.
[33] Gaggin HK,Januzzi JL, Acta BB.Biomarkers and diagnostics in heart failure[J].Biochim Biophys Acta,2013,1832(12):2442-2450.
[34] Matsubara J,Sugiyama S,Nozaki T,et al.Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction[J].J Am Coll Cardiol,2011,57(7):861-869.
[35] Suzuki S,Shishido T,Funayama A,et al.Long pentraxin PTX3 exacerbates pressure overload induced left ventricular dysfunction[J]. PLoS One,2013,8(1):e53133.
相似文献/References:
[1]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(1):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[2]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[3]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[4]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[5]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[6]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[7]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(1):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[8]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(1):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[9]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(1):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
[10]李海威 姜红 李宪伦.射血分数保留性心力衰竭患者运动康复的研究进展[J].心血管病学进展,2019,(8):1146.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.019]
LI Haiwei,JIANG Hong,LI Xianlun.Exercise Rehabilitation in Patients with Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2019,(1):1146.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.019]